Major C-suite changes to potential competitors are key factors in the rise Viking Therapy (NASDAQ: VKTX) On Friday, the stock closed a 3% trade fair. This figure is 0.7% above the benchmark S&P 500 index.
That competitor is Novo Nordiskannounced that its current CEO Lars Jørgensen will remove his position.
It is a Denmark-based pharmaceutical company that gradually emerged earlier in the decade when its Wegovy became the first GLP-1 drug approved by the U.S. Food and Drug Administration (FDA) to obesity.
The European company is a potential competitor because likewise, the Vikings' VK2735 is an investigational weight loss treatment that has also gained a certain reputation. The drug performed well in the second phase of clinical testing, hoping that it will not only win FDA approval, but will also become a hot item in the hot market when commercialized.
Of course, what happened to Novo Nordisk does not directly affect Viking's operations, but most importantly its development activities. Nevertheless, any change in company leadership could affect its business dynamics, with the weight loss drug segment growing more competitive. Even a small stumble or personnel decision could mean a loss of market share for Danish Pharmaceuticals.
That being said, the reaction to Viking stock seems a bit too high, especially given that Novo Nordisk is a legendary business that will likely be careful when replacing its CEO. Viking investors should pay more attention to the progress of VK2735 than what happens outside the company.
Before buying stocks in Viking Therapeutics, consider the following:
this Motley Fool Stock Advisor The analyst team just confirmed what they think is 10 Best Stocks Investors are buying now…and Viking therapeutics are not one of them. Ten stocks with layoffs could generate monster returns in the coming years.
When to consider Netflix On this list on December 17, 2004...If you invested $1,000 when you suggested, You will have $635,275! * Or when Nvidia This list was listed on April 15, 2005...If you invested $1,000 when you suggested, You will have $826,385! *
Now, it's worth noting Stock ConsultantThe overall average return is 967% - Compared to market impulses 171% For the S&P 500 index. Don't miss the latest top ten list, available when you join Stock Consultant.
View 10 stocks »